Metallo-salen complexes show promise towards treatment of leukemia

Variable Ordering Heuristics Show Promise

ADCs Show Promise in Leukemias.

According to a phase III study, the antibody-drug conjugate inotuzumab ozogamicin is more likely to induce complete remissions, with full or incomplete hematologic recovery, in patients with relapsed or refractory acute lymphocytic leukemia. Data from a phase I study of another antibody-drug conjugate, vadastuximab talirine, demonstrates that it is safe and effective against acute myeloid leuke...

Binuclear (salen)osmium phosphinidine and phosphiniminato complexes.

The preparation of a number of binuclear (salen)osmium phosphinidine and phosphiniminato complexes using various strategies are described. Treatment of [Os(VI)(N)(L(1))(sol)](X) (sol = H(2)O or MeOH) with PPh(3) affords an osmium(IV) phosphinidine complex [Os(IV){N(H)PPh(3)}(L(1))(OMe)](X) (X = PF(6)1a, ClO(4)1b). If the reaction is carried out in CH(2)Cl(2) in the presence of excess pyrazine t...

Highly electrophilic (salen)ruthenium(VI) nitrido complexes.

A series of cationic ruthenium(VI) nitrido species containing the cyclohexyl-bridged salen ligand (L) and its derivatives, [RuVI(N)(L)]+, have been prepared by treatment of [NBun4][RuVI(N)Cl4] with H2L in methanol. The structure of [RuVI(N)(L)](ClO4) (1a) has been determined by X-ray crystallography, d(RuN) = 1.592 A. In solvents such as DMF or DMSO, [RuVI(N)(L)]+ undergoes a facile N...N coupl...

Agents to control bleeding show promise.

Every year, thousands of patients develop deep vein thrombosis (DVT) and are at risk of pulmonary embolism after undergoing surgeries, particularly orthopedic procedures in the hips and legs. Although low-molecular-weight heparin is considered the standard therapy for DVT and other forms of venous thromboembolism, it is far from an ideal anticoagulant. Its drawbacks include the need for daily i...